BATON ROUGE, La. (BRPROUD) – A potential treatment for COVID-19 using existing drugs developed by Skymount Medical using an artificial intelligence platform developed by Louisiana State University was recently approved for clinical trials in the United Kingdom by the country’s Medicines and Healthcare products Regulatory Agency.

The artificial intelligence platform, DeepDrug AI, was developed by Supratik Mukhopadhyay, a professor in the LSU Department of Environmental Sciences, and Michal Brylinski, an associate professor in the LSU Department of Biological Sciences. The new oral therapeutic treatment is comprised of a cancer medication and an anti-parasitic agent, both of which have already previously been approved by the U. S. Food and Drug Administration.

“This is a significant milestone for Skymount Medical, the LSU DeepDrug AI platform, and patients suffering from mild-to-moderate COVID-19,” said Kishor Wasan, chief medical and scientific officer at Skymount Medical. “There are limited oral medication options to alleviate COVID-19 symptoms in adult patients who are not hospitalized, and our drug combination or single drug would be administered at the first sign of infection, reducing the amount and duration of symptoms, and allowing patients to avoid hospitalization. With our drug combination already in a human pilot study in the United States, we are pleased to expand the reach of this combination therapy internationally.”

LSU says the study will be a “double-blind intervention” comparing the AI-developed treatment and a single antiviral drug to a placebo. It will determine the impact these therapies will have on the length and severity of COVID-19 symptoms.